QTTB · Insider Trading
Q32 Bio Inc. Common Stock
Every open-market purchase and sale reported by QTTB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-14 | Shelia M. Violette | Chief Scientific Officer | Sell | −917 | −$7.63K |
| 2026-10-14 | Lee Kalowski | CFO and President | Sell | −1,301 | −$10.82K |
| 2026-10-14 | Jodie Pope Morrison | CEO | Sell | −3,221 | −$26.80K |
| 2026-08-27 | Shelia M. Violette | Chief Scientific Officer | Sell | −2,798 | −$46.33K |
| 2026-08-27 | Lee Kalowski | CFO and President | Sell | −3,972 | −$65.78K |
| 2026-08-27 | Jodie Pope Morrison | CEO | Sell | −9,845 | −$163.03K |
| 2026-07-21 | Mark T Iwicki | Director | A | +10,826 deriv. | — |
| 2026-07-21 | Isaac Manke | Director | A | +10,826 deriv. | — |
| 2026-07-21 | Sven Ante Lundberg | Director | A | +10,826 deriv. | — |
| 2026-07-21 | Arthur Tzianabos | Director | A | +10,826 deriv. | — |
| 2026-07-21 | David S. Grayzel | Director | A | +10,826 deriv. | — |
| 2026-07-21 | Mary Thistle | Director | A | +10,826 deriv. | — |
| 2026-07-21 | Kathleen Laporte | Director | A | +10,826 deriv. | — |
| 2026-07-21 | Diyong Xu | Director | A | +10,826 deriv. | — |
| 2026-07-20 | Jodie Pope Morrison | CEO | A | +132,000 | — |
| 2026-07-20 | Shelia M. Violette | Chief Scientific Officer | A | +37,500 | — |
| 2026-07-20 | Lee Kalowski | CFO and President | A | +53,250 | — |
| 2026-07-02 | Isaac Manke | Director | M | +53,521 | +$149.86K |
| 2026-06-16 | Kathleen Laporte | Director | A | +9,810 deriv. | — |
| 2026-06-16 | Mark T Iwicki | Director | A | +9,810 deriv. | — |
| 2026-06-16 | David S. Grayzel | Director | A | +9,810 deriv. | — |
| 2026-06-16 | Mary Thistle | Director | A | +9,810 deriv. | — |
| 2026-06-16 | Arthur Tzianabos | Director | A | +9,810 deriv. | — |
| 2026-06-16 | Isaac Manke | Director | A | +9,810 deriv. | — |
| 2026-06-16 | Diyong Xu | Director | A | +9,810 deriv. | — |
| 2026-06-16 | Sven Ante Lundberg | Director | A | +9,810 deriv. | — |
| 2026-06-01 | OrbiMed Genesis GP LLC | Director | Buy | +1,875,000 | +$15.00M |
| 2026-06-01 | Diyong Xu | Director | Buy | +1,875,000 | +$15.00M |
| 2026-03-20 | Jodie Pope Morrison | CEO | A | +132,000 | — |
| 2026-03-20 | Lee Kalowski | CFO and President | A | +53,250 | — |
| 2026-03-20 | Shelia M. Violette | Chief Scientific Officer | A | +37,500 | — |
| 2026-02-27 | Jodie Pope Morrison | CEO | Sell | −9,896 | −$44.67K |
| 2026-02-27 | Lee Kalowski | CFO and President | Sell | −3,995 | −$18.04K |
| 2026-02-27 | Shelia M. Violette | Chief Scientific Officer | Sell | −2,815 | −$12.71K |
| 2026-01-30 | Sven Ante Lundberg | Director | A | +20,363 deriv. | — |
| 2026-01-30 | David S. Grayzel | Director | A | +16,363 deriv. | — |
| 2026-01-30 | Kathleen Laporte | Director | A | +23,272 deriv. | — |
| 2025-12-04 | Jodie Pope Morrison | CEO | Sell | −22,506 | −$77.87K |
| 2025-12-04 | Lee Kalowski | CFO and President | Sell | −9,072 | −$31.40K |
| 2025-10-27 | Arthur Tzianabos | Director | A | +53,521 deriv. | — |
| 2025-10-27 | Mark T Iwicki | Director | A | +53,521 deriv. | — |
| 2025-10-27 | Sven Ante Lundberg | Director | A | +53,521 deriv. | — |
| 2025-10-27 | Kathleen Laporte | Director | A | +53,521 deriv. | — |
| 2025-10-27 | Mary Thistle | Director | A | +53,521 deriv. | — |
| 2025-10-27 | Diyong Xu | Director | A | +53,521 deriv. | — |
| 2025-10-27 | David S. Grayzel | Director | A | +53,521 deriv. | — |
| 2025-10-27 | Isaac Manke | Director | A | +53,521 deriv. | — |
| 2025-08-28 | Shelia M. Violette | Chief Scientific Officer | Sell | −2,990 | −$5.38K |
| 2025-08-28 | Lee Kalowski | CFO and President | Sell | −4,240 | −$7.64K |
| 2025-08-28 | Jodie Pope Morrison | CEO | Sell | −10,494 | −$18.90K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| OrbiMed Genesis GP LLC | Director | 625,000 | $5.30M |
| Diyong Xu | Director | 625,000 | $5.30M |
| Jodie Pope Morrison | CEO | 340,038 | $2.88M |
| Shelia M. Violette | Chief Scientific Officer | 163,131 | $1.38M |
| Lee Kalowski | CFO and President | 137,170 | $1.16M |
| Isaac Manke | Director | 53,521 | $453.86K |
| Jason Campagna | Chief Medical Officer | 37,500 | $318.00K |
| Arthur Tzianabos | Director | 7,983 | $67.70K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the QTTB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.